Advertisement

Correction to: Multiple HPV infections in female sex workers in Western Kenya: implications for prophylactic vaccines within this sub population

  • Sonia MenonEmail author
  • Davy van den Broeck
  • Rodolfo Rossi
  • Emilomo Ogbe
  • Hillary Mabeya
Open Access
Correction
  • 89 Downloads

Correction to: Infectious Agents and Cancer 2017 12:2 DOI  https://doi.org/10.1186/s13027-016-0114-5

Following publication of the original article [1], the author reported that some values in Tables 2, 3, 4, 5 and 6. The correct Tables are as given below:
Table 2

reports the prevalence of cervical abnormalities observed in the sample (N = 599)

Cytological status

n

% of FSW (95%CI)

Normal cytology

512

85.5% (82.4–88.2)

ASC-US

10

1.7% (0.8–3.04)

LSIL

63

10.5% (8.2–13.3)

HSIL

14

2.3% (12.8–3.9)

Excluded samples due to poor cell quality

17

2.8%

Table 3

reports the prevalence of each HPV genotypes and STIs

pHR/ HR HPV Genotype

Frequency (n)

Percentage

HPV 16 (N = 616)

99

16.1%

HPV 18 (N = 616)

68

11.0%

HPV 31 (N = 616)

49

8.0%

HPV 33 (N = 616)

2

0.3%

HPV 35 (N = 616)

70

11.4%

HPV 39 (N = 616)

48

7.8%

HPV 51 (N = 615)

52

8.5%

HPV 53 (N = 616)

68

11.0%

HPV 56 (N = 616)

45

7.3%

HPV 58 (N = 616)

30

4.9%

HPV 59 (N = 616)

75

12.2%

HPV 66 (N = 616)

60

9.7%

HPV 68 (N = 616)

9

1.5%

BV and STIs

 BV* (N = 555)

268

48.3%

 TV (N = 609)

191

31.4%

 Candida (N = 609)

121

19.9%

Table 4

reports the prevalence of each HPV genotype among HPV-positive women with abnormal cytology

HPV genotype

Abnormal cytology

% (N = 84)

HPV 16

24

28.6%

HPV 18

15

17.9%

HPV 31

13

15.5%

HPV 33

1

1.2%

HPV 35

18

21.4%

HPV 39

13

15.5%

HPV 45

9

10.7%

HPV 51

18

21.4%

HPV 52

26

31.0%

HPV 53

21

25.0%

HPV 56

13

15.5%

HPV 58

4

4.8%

HPV 59

17

20.2%

HPV 66

9

10.7%

HPV 68

4

4.8%

Table 5

most prevalent pairing occurrences in women with abnormal cytology

Prevalent pairings in abnormal cytology in HIV-negative women: N = 35)

(n = in normal cytology)

n = abnormal cytology

 HPV 18 and 31

2

3

 HPV 31 and 52

7

2

Prevalent pairings in HIV infected women with abnormal cytology: N = 52)

 HPV 16 and 39

2

6

 HPV 16 and 52

9

7

 HPV 16 and 51

4

5

 HPV 16 and 53

10

7

 HPV 18 and 52

12

5

 HPV 18 and 53

8

5

 HPV 31 and 51

2

5

 HPV 35 and 51

2

5

 HPV 35 and 53

4

7

 HPV 45 and 53

0

6

 HPV 45 and 59

2

5

 HPV 51 and 53

2

7

 HPV 51 and 56

1

6

 HPV 52 and 56

3

6

 HPV 53 and 56

1

5

Table 6

association between STI, specific pHR/HR HPV genotypes and abnormal cytology; OR from

STI or HPV genotype

OR Model 1 (95%CI)

p-value

OR Model 2 (95%CI)

p-value

BV

0.9 (0.6–1.5)

0.8

0.8 (0.5–1.4)

0.5

TV

24.8 (12.7–48.3)

< 0.001

30.0 (14.1–62.9)

< 0.001

Candida spp

1.0 (0.5–1.7)

1.0

0.9 (0.5–1.7)

0.7

Multiple HPV infection

5.3 (2.9–9.7)

< 0.001

3.7 (1.9–7.3)

< 0.001

HPV 16

1.9 (0.8–4.5)

0.1

1.2 (0.5–3.2)

0.5

HPV 18

0.8 (0.3–2.1)

0.7

1.04 (0.4–2.8)

0.9

HPV 31

0.5 (0.2–1.5)

0.2

0.6 (0.2–1.7)

0.3

HPV 33

3.9 (0.05–293.9)

0.5

2.8 (0.03–254.6)

0.6

HPV 35

1.3 (0.6–3.0)

0.5

1.1 (0.5–2.7)

0.9

HPV 39

3.3 (1.3–8.7)

0.03

2.5 (0.9–7.1)

0.09

HPV 51

3.7 (1.6–8.6)

0.002

3.7 (1.5–9.0)

0.004

HPV 52

6.1 (2.8–13.3)

< 0.001

4.0 (1.6–8.2)

0.002

HPV 53

2.0 (0.8–4.9)

0.1

1.4; (0.5–3.8)

0.5

HPV 56

2.5 (1.0–6.6)

0.06

2.0 (0.7–5.7)

0.2

HPV 58

0.9 (0.2–3.6)

0.9

1.1 (0.3–5.2)

0.9

HPV 66

1.2 (0.5–3.0)

0.7

1.0 (0.4–3.0)

0.9

HPV 68

1.7 (0.2–17.0)

0.7

0.8 (0.1–7.4)

0.8

Logistic regression; p-value from LRT

Model 1: OR adjusting for age, pHR/HR HPV genotypes, STIs

Model 2: OR adjusting for age and pHR/HR genotypes, STIs and HIV

Reference

  1. 1.
    Menon S, et al. Multiple HPV infections in female sex workers in Western Kenya: implications for prophylactic vaccines within this sub population. Infect Agent Cancer. 2017;12(2).  https://doi.org/10.1186/s13027-016-0114-5.

Copyright information

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • Sonia Menon
    • 1
    • 5
    Email author
  • Davy van den Broeck
    • 1
    • 4
  • Rodolfo Rossi
    • 3
  • Emilomo Ogbe
    • 1
  • Hillary Mabeya
    • 1
    • 2
  1. 1.International Centre for Reproductive health, Department of Obstetrics and GynaecologyGhent UniversityGhentBelgium
  2. 2.Gynocare Fistula CentreMoi UniversityEldoretKenya
  3. 3.AMBIOR (Applied Molecular Biology Research Group)AntwerpenBelgium
  4. 4.Faculty of Medicine and Health Sciences, Laboratory of Cell Biology & HistologyUniversity of AntwerpAntwerpBelgium
  5. 5.CDC Foundation AtlantaAtlantaUSA

Personalised recommendations